Amiodarone: Uses, Thyroid Effects and Other Safety Findings
Amiodarone is one of the most widely used drugs for an irregular heartbeat, and also one of the drugs with the longest list of recorded side effects. It is rich in iodine and stays in the body for weeks to months, and both facts shape what the research records about it: changes in the thyroid gland, the lungs, the liver, the eyes, the skin and the nerves, and interactions with other common heart medicines. This page reports what guidelines, large population studies and reviews have found, with the numbers exactly as those records give them.
Table of Contents
- A Class III Heart-Rhythm Drug
- A Large Iodine Load and a Slow Exit
- What Placebo-Controlled Trials Measured
- Thyroid Blood Tests Shift
- Amiodarone-Induced Hypothyroidism
- Two Types of Amiodarone-Induced Thyrotoxicosis
- How Often Thyroid Problems Occur
- Lung Toxicity
- Liver Findings
- Eye Findings
- Skin Findings
- Nerve Findings
- Warfarin, Digoxin and Statin Interactions
- Monitoring Described by Guidelines
- What Remains Unknown
- Key Research Papers
- Connections
- Featured Videos
Amiodarone Is a Class III Heart-Rhythm Drug
Amiodarone is an antiarrhythmic drug: a medicine used to control abnormal heart rhythms. A 1991 pharmacology review describes it as a unique agent that was originally developed as a vasodilator (a drug that widens blood vessels) and is classified electrophysiologically as a Type III antiarrhythmic, while also having nonspecific antisympathetic effects and direct effects on the heart's fast channels. A 2020 clinical review adds that, although it is classified as class III, it affects all phases of the cardiac action potential (the electrical cycle of each heartbeat), and a 2024 review states that it shows antiarrhythmic properties across all four classes of antiarrhythmic drugs.
Its official approval is narrower than its use. A 2007 evidence review in JAMA states that amiodarone is approved by the US Food and Drug Administration only for refractory ventricular arrhythmias (dangerous rhythms arising in the lower chambers of the heart that have not responded to other treatment), yet it is one of the most frequently prescribed antiarrhythmic medications in the United States. That review found evidence for these settings:
- Atrial fibrillation with a weak heart muscle. The review states amiodarone may have clinical value as first-line treatment for atrial fibrillation in people with left ventricular dysfunction and heart failure, though other agents are available.
- Sustained ventricular tachycardia. It is described as useful in the acute management of sustained ventricular tachyarrhythmias, regardless of whether blood pressure is stable.
- Heart surgery. The review states that the only role for preventive (prophylactic) amiodarone is in the period around cardiac surgery.
- Implanted defibrillators. It may reduce the number of shocks when added to an implantable cardioverter-defibrillator.
The 2024 review states that amiodarone is highly effective in maintaining a normal (sinus) rhythm in people with paroxysmal atrial fibrillation and plays a crucial role in preventing a range of ventricular arrhythmias. The conditions themselves are covered on the Atrial Fibrillation and Ventricular Tachycardia pages.
Each Dose Carries a Large Iodine Load and Leaves the Body Slowly
Iodine content. A 2021 review in the Journal of Clinical Endocrinology and Metabolism describes amiodarone as a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones. The review states that the breakdown (deiodination) of amiodarone releases large amounts of iodine that can impair thyroid function. Why a large iodine load can inflame or disturb the thyroid is explained on the companion page Iodine Excess: Thyroiditis.
Absorption. The drug is absorbed unevenly from the gut. The 1991 review gives an oral bioavailability of 20–80%; a 1984 pharmacokinetics review describes absorption as erratic and unpredictable, with oral bioavailability ranging from 22 to 86%. In vitro, 96.3% of amiodarone is bound to blood proteins, according to the 1984 review.
Storage in fat. Amiodarone is highly lipophilic (fat-loving). The 1984 review states that adipose tissue and skeletal muscle accumulate large amounts of the drug during long-term treatment. The 1991 review describes exceptionally high tissue-to-plasma partition coefficients and notes that its main breakdown product, mono-N-desethylamiodarone, is itself an antiarrhythmic.
A very long half-life. The time the body takes to clear half of the drug depends on how long it has been taken:
- The 1991 review states that the terminal half-life is both long and variable (9–77 days), because the drug is slowly mobilised out of fat cells.
- The 1984 review states that after a single dose the plasma half-life has been reported in the range of 3.2 to 79.7 hours, but after withdrawal of long-term treatment it is as long as 100 days.
- The 2024 review describes a half-life that can range from several weeks to months, resulting in prolonged effects even after the drug is stopped.
The 1984 review also records that less than 1% of a dose leaves unchanged in the urine, that placental transfer of amiodarone has been demonstrated in humans, and that its blood profile is not changed by dialysis.
Placebo-Controlled Trials Measure the Overall Side-Effect Burden
Two meta-analyses pooled randomised trials that compared amiodarone with a dummy pill (placebo). They give the clearest picture of which side effects are truly caused by the drug, because the placebo group shows how often the same problems occur anyway.
The 1997 low-dose meta-analysis. Pooling 4 double-blind trials with 1,465 patients (738 given amiodarone, 727 placebo) and a mean daily dose of 152 to 330 mg for at least 12 months, the authors found odds similar to placebo for liver and gastrointestinal side effects, but significantly higher odds for:
- thyroid side effects (odds ratio 4.2)
- ocular (eye) side effects (odds ratio 3.4)
- skin side effects (odds ratio 2.5)
- bradycardia, a slow heart rate (odds ratio 2.2)
- neurologic side effects (odds ratio 2.0)
There was a trend toward more lung toxicity that did not reach statistical significance (p = 0.07). The unadjusted rate of stopping the drug was 22.9% with amiodarone and 15.4% with placebo. The authors concluded that low-dose amiodarone may be well tolerated but is not free of adverse effects.
The 2019 meta-analysis. A larger pooling of 43 randomised trials with 11,395 patients (5,792 given amiodarone, 5,603 placebo) reported side-effect rates per 10,000 person-years:
- Thyroid: 201 with amiodarone versus 42 with placebo (relative risk 4.44)
- Hepatic (liver): 54 versus 25 (relative risk 2.27)
- Skin: 81 versus 23 (relative risk 1.99)
- Cardiac: 771 versus 450 (relative risk 1.94)
- Neurological: 140 versus 76 (relative risk 1.93)
- Pulmonary (lung): 129 versus 74 (relative risk 1.77)
Low-dose amiodarone was not associated with a statistically significant increase in lung side effects in that analysis, but was still associated with thyroid and liver side effects. The authors wrote that the overall rate of adverse events was low and severe adverse events were rare.
A long-term follow-up in everyday practice. A French prospective study followed 98 people newly started on amiodarone (mean age 72.6 years) for a mean of 38 months. Side effects occurred at a rate of 13.91 per 100 person-years. Recorded were 13 cases of hypothyroidism, 5 of hyperthyroidism, 10 of slow heart rate or conduction problems, 7 of photosensitivity, 3 of interstitial pneumonitis, 2 of peripheral neuropathy, 1 storage disease, 1 tremor and 1 of gastrointestinal upset. Thyroid and heart side effects occurred mainly during the first 6 months, and none was fatal in that study.
Thyroid Blood Tests Shift Even in a Healthy Gland
A 2001 review in Endocrine Reviews by Martino, Bartalena, Bogazzi and Braverman states that amiodarone often causes changes in thyroid function tests, typically a rise in serum thyroxine (T4) and reverse T3 and a fall in serum triiodothyronine (T3). The review relates these changes mainly to the drug's blocking of 5′-deiodinase, the enzyme that turns T4 into the active hormone T3. A 1989 review in Clinical Chemistry describes the same pattern.
The 2018 European Thyroid Association guideline separates these laboratory changes from true thyroid disease: it states that treatment with amiodarone is associated with changes in thyroid function tests, but also with thyroid dysfunction — amiodarone-induced hypothyroidism and amiodarone-induced thyrotoxicosis. The 2021 review adds that not only the excess iodine but also amiodarone itself, or its breakdown product desethylamiodarone, may cause thyroid dysfunction by direct toxicity to thyroid cells. How these tests are read is covered on the Thyroid Panel page.
Amiodarone-Induced Hypothyroidism Is the Underactive Form
In amiodarone-induced hypothyroidism, the gland makes too little hormone. The 2018 European Thyroid Association guideline states that both this condition and the overactive form may develop in apparently normal thyroid glands or in glands with underlying thyroid abnormalities.
- Cause. The 2001 Endocrine Reviews paper relates iodine-induced hypothyroidism on amiodarone to a failure to escape from the acute Wolff–Chaikoff effect (the thyroid's normal temporary shutdown after an iodine surge) because of defects in hormone production, and, in people with positive thyroid antibody tests, to coexisting Hashimoto's thyroiditis.
- Who is at higher risk. The same review calls pre-existing Hashimoto's thyroiditis a definite risk factor.
- Treatment the guideline describes. The 2018 guideline states that amiodarone-induced hypothyroidism does not require stopping amiodarone; overt cases are treated with levothyroxine replacement, while subclinical (mild, test-only) forms may be followed without treatment.
The general condition is described on the Hypothyroidism page.
The 2018 European Guideline Describes Two Types of Overactive Thyroid
Amiodarone-induced thyrotoxicosis means too much thyroid hormone in the blood caused by the drug. The 2018 European Thyroid Association guideline recognises two main types:
- Type 1 is a form of iodine-induced hyperthyroidism occurring in nodular goitres or latent Graves' disease — a gland that was already abnormal makes extra hormone from the drug's iodine.
- Type 2 results from destructive thyroiditis in a normal thyroid gland — the gland is injured and leaks hormone it had already stored.
- Mixed or indefinite forms exist, because both mechanisms can act together.
The guideline describes different treatments for each type:
- Type 1 is best treated with thionamides (antithyroid drugs), which may be combined for a few weeks with sodium perchlorate to make the gland more sensitive to them. Once normal thyroid function has been restored, the guideline states that type 1 patients be treated with thyroidectomy (surgical removal of the gland) or radioiodine.
- Type 2 is treated with oral glucocorticoids (steroids). Once normal thyroid function has been restored, type 2 patients are followed up without treatment.
- Mixed or indefinite forms are treated with thionamides. Oral glucocorticoids can be added from the beginning if the precise diagnosis is uncertain, or after a few weeks if the response to thionamides alone is poor.
- The guideline states that the decision to continue or stop amiodarone should be individualised in relation to cardiovascular risk and taken jointly by specialist cardiologists and endocrinologists. When heart conditions are deteriorating rapidly, emergency thyroidectomy may be required for all forms.
The 2001 Endocrine Reviews paper adds that radioiodine therapy is usually not feasible because the gland's radioiodine uptake is low, and that thyroidectomy can be performed in cases resistant to medical therapy, with a slightly increased surgical risk. The broader conditions are covered on the Hyperthyroidism page and, for the iodine side, the Iodine Excess: Thyroid Dysfunction page.
Thyroid Problems Are Common in Long-Term Users
Estimates vary with the population, its iodine intake, and how long people were followed:
- Korea, 27,023 people. A 2025 nationwide study used the Korean National Health Insurance database to follow 27,023 consecutive patients treated with amiodarone for arrhythmia, in an iodine-sufficient area. During a mean follow-up of 6.4 years, 1,326 (4.9%) developed thyrotoxicosis and 3,121 (11.5%) developed hypothyroidism — 6.92 and 17.1 cases per 1,000 person-years. Chronic kidney disease (hazard ratio 1.46) and Hashimoto's thyroiditis (hazard ratio 2.00) were linked to thyrotoxicosis; female sex (hazard ratio 1.22), diabetes (1.14), chronic kidney disease (1.18) and Hashimoto's thyroiditis (2.26) were linked to hypothyroidism.
- Iceland, every new user in 2014. A 2025 study followed all 262 people in Iceland with a normal thyroid who filled a first amiodarone prescription in 2014. The overall incidence was 9.2% for thyrotoxicosis, 13.4% for hypothyroidism and 22.5% for any thyroid dysfunction. The 5-year cumulative incidence was 19.0%, 21.8% and 38.5% respectively. The highest yearly rate of thyrotoxicosis, 9.8%, came in the third year of treatment; for hypothyroidism it was 9.8% in the first year. Among people with thyrotoxicosis, 8% later became hypothyroid, 8% had a thyroidectomy, 36% were hospitalised and 4% died; 91.7% of people with hypothyroidism were placed on thyroid hormone replacement. The authors write that nearly 40% of patients taking amiodarone for 5 years acquire thyroid dysfunction, higher than previously described, and cite earlier prevalence figures of 1.2% to 12% for thyrotoxicosis and 12%–17% for hypothyroidism.
- Reviews. The 2001 Endocrine Reviews paper reports overt thyroid dysfunction in 14–18% of amiodarone-treated patients. The 2021 review puts hypothyroidism or thyrotoxicosis at about 20% of patients given the drug. A 2007 JAMA review lists hypothyroidism at 6% and hyperthyroidism at 0.9%–2%.
- Scotland, 1,413 long-term users. A UK population study from Tayside (1989–2011) recorded an abnormal thyroid-stimulating hormone (TSH) result in 16% of patients; 140 (10%) required thyroxine replacement and 40 (3%) required medication for an overactive thyroid.
The Korean authors note that hypothyroidism was more common than thyrotoxicosis in an area with sufficient iodine intake.
Lung Toxicity Is the Most Feared Finding
Several records name lung injury as amiodarone's most serious side effect: a 2007 Japanese study calls amiodarone-induced pulmonary toxicity the most serious side effect, a 2024 Israeli study calls amiodarone-related interstitial lung disease (scarring and inflammation of lung tissue) the most severe adverse effect, and a 1999 review states that, in terms of its toxicity, amiodarone remains the most feared of the antiarrhythmic agents.
How often it occurs. The estimates disagree widely, which is itself a finding:
- A 2010 review in Drug Safety states that lung adverse effects occur in approximately 5% of treated patients.
- The 1999 review calls pulmonary toxicity infrequent (under 1% incidence) but sometimes fatal, and states that, lacking a diagnostic gold standard, it is often overdiagnosed — placing patients at risk from overlooked heart failure, infections and recurrent arrhythmias after the drug is withdrawn.
- The 2007 JAMA review lists pulmonary toxicity at 1%–17%.
- In 500 consecutive Japanese patients on a mean maintenance dose of 141 mg daily, followed for a mean of 48 months, the cumulative incidence was 4.2%, 7.8% and 10.6% at 1, 3 and 5 years. Older age and a higher maintenance dose were risk factors. The authors concluded that even at low dose, amiodarone shows substantial pulmonary toxicity.
- In the 2024 Israeli nationwide study of people with atrial fibrillation, 6,039 amiodarone users were matched with unexposed controls (median age 73.3 years). After a mean of 4.2 years, interstitial lung disease occurred in 242 (2.0%) patients. After statistical weighting, amiodarone exposure was not significantly associated with interstitial lung disease (hazard ratio 1.45, p = 0.09). The authors describe a trend towards increased risk (15%–45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of primary lung cancer, and a lower risk of death from any cause (hazard ratio 0.65) in this observational data.
What it looks like. The 2010 review states that lung effects may develop from the first few days of treatment to several years later, with an onset that may be insidious or rapidly progressive. It lists cough, new shadows on chest imaging and reduced lung diffusing capacity as the cardinal elements of diagnosis, after infection, cancer and fluid on the lungs have been carefully excluded. The 1999 review describes an indolent onset of cough, malaise and fever with patchy shadows at the edges of the lungs and severely decreased diffusion capacity.
Who the research raises concerns for. The 2010 review links lung complications to older age, duration of treatment and cumulative dose, high levels of the desethyl metabolite, previous heart or chest surgery or use of high oxygen mixtures, use of iodinated contrast media, and probably pre-existing lung disease and coexisting respiratory infections. The 1999 review states that people with pre-existing lung disease appear to be more at risk.
Outcome. The 2010 review reports mortality ranging from 9% for those who develop chronic pneumonia to 50% for those who develop acute respiratory distress syndrome. It describes stopping the drug, controlling risk factors and, in more severe cases, corticosteroids as possibly of therapeutic value. The 1999 review states that most cases recover once amiodarone is stopped, and that steroids are commonly used but of unproved efficacy.
Liver Enzyme Rises Are Common, Liver Failure Is Rare
A 2008 review of amiodarone hepatotoxicity states that liver injury is mostly associated with long-term oral use, but has also been reported early during intravenous administration and months after the drug was stopped. In the majority of patients it is discovered incidentally during routine liver blood tests, and the review states that it rarely develops into symptomatic liver injury or failure.
- The 2007 JAMA review lists elevated liver enzyme levels at 15%–30%, and hepatitis and cirrhosis at under 3% (0.6% annually).
- In the Scottish population study, 117 (9.5%) patients had an alanine aminotransferase (ALT, a liver enzyme) level of three times the upper limit of normal during follow-up. Total amiodarone exposure increased the likelihood of abnormal liver and thyroid tests 2.5-fold after 4 years of therapy.
- The two placebo-controlled meta-analyses differ: the 1997 low-dose analysis found odds similar to placebo for liver side effects, while the 2019 analysis of 43 trials found 54 versus 25 hepatic events per 10,000 person-years (relative risk 2.27), still present at low dose.
The 2008 review notes that prospective clinical studies have been sparse and that there has been little consensus among experts on the best way to monitor for side effects.
Corneal Deposits Are Near-Universal, Optic Nerve Damage Is Uncommon
Corneal deposits. A 1999 review states that corneal microdeposits (tiny deposits in the clear front surface of the eye) are almost ubiquitous in people treated with amiodarone, but are for the most part benign and produce no change in visual acuity. The 2007 JAMA review lists them at over 90%. The 1999 review adds that the absence of microdeposits prompts physicians to check whether the drug is being absorbed or taken as prescribed.
Optic neuropathy. Damage to the optic nerve is far rarer and far more serious:
- The 2007 JAMA review lists optic neuropathy or neuritis at up to 1%–2%.
- A 2015 Taiwanese nationwide study compared 6,175 newly treated patients with 24,700 matched controls over a mean of 688 days. Optic neuropathy developed in 17 amiodarone-treated patients (0.3%) and 30 controls (0.1%) — a 2-fold increased risk (hazard ratio 2.09). The risk remained significant in men (hazard ratio 3.05) but not in women, and there was a trend toward higher risk with longer treatment. A higher daily dose did not increase the risk.
- A 2012 review of 296 reports — 214 from the US Food and Drug Administration's Adverse Event Reporting System, 59 published case reports and 23 from clinical trials — found that vision loss came after a mean of 9 months of therapy (range 1–84 months). An insidious onset was the most common presentation (44%), nearly one third of cases had no symptoms, and swelling of the optic disc was present in 85%. After the drug was stopped, 58% had improved visual acuity, 21% were unchanged and 21% got worse; legal blindness (worse than 20/200) in at least one eye was noted in 20% of cases. These are reported cases, not a measure of how often the condition occurs.
The question of cause is not fully settled. The 1999 review states that no causal link between amiodarone and optic neuropathy had been proved, noting that people treated with amiodarone often have ischaemic disease or diabetes, which affect the retina and optic nerve. A 2022 review describes amiodarone-associated optic neuropathy as a complex diagnosis that has to be distinguished from non-arteritic ischaemic optic neuropathy, because the two share the same at-risk population. In the 1997 placebo-controlled analysis, eye side effects had an odds ratio of 3.4.
Sun Sensitivity and Blue-Grey Skin Are the Skin Findings
- Photosensitivity. The 2007 JAMA review lists photosensitivity (an exaggerated reaction to sunlight) at 25%–75%. In the French long-term follow-up, photosensitivity was among the most frequent side effects, with 7 cases (2.27 per 100 person-years).
- Blue-grey discolouration. The same JAMA review lists blue-gray skin discoloration at 4%–9%.
- Placebo comparison. Skin side effects had an odds ratio of 2.5 in the 1997 low-dose meta-analysis, and occurred at 81 versus 23 per 10,000 person-years (relative risk 1.99) in the 2019 meta-analysis.
Nerve Findings Include Peripheral Neuropathy and Tremor
- The 2007 JAMA review lists peripheral neuropathy (damage to the nerves of the hands and feet) at 0.3% annually.
- The French long-term follow-up recorded 2 peripheral neuropathies (0.65 per 100 person-years) and 1 tremor among 98 patients.
- Neurologic side effects had an odds ratio of 2.0 in the 1997 low-dose meta-analysis, and neurological events occurred at 140 versus 76 per 10,000 person-years (relative risk 1.93) in the 2019 meta-analysis.
Warfarin, Digoxin and Statin Levels Rise With Amiodarone
A 1989 review of amiodarone's drug interactions states that its major mechanism is inhibition of drug breakdown in the liver, although it can also change the absorption, protein binding and kidney excretion of other drugs. It significantly increases blood levels of digoxin, warfarin, several class I antiarrhythmic drugs (quinidine, procainamide, aprindine and flecainide) and phenytoin, in some cases with clear signs of toxicity. The review states that in most cases 20 to 50% reductions in the doses of the affected drugs are necessary to offset these changes. With beta-blockers such as propranolol and calcium channel blockers such as diltiazem, the review describes additive effects on heart rhythm and blood pressure (slow heart rate and sinus arrest) rather than changes in drug levels.
Warfarin.
- Mechanism. A 1992 study in healthy volunteers found that amiodarone lowered the body's clearance of both forms (R and S) of warfarin, and that the stronger anticoagulant effect is attributable to inhibition of the liver enzyme CYP2C9, which mainly breaks down S-warfarin.
- Bleeding and clotting tests. A 2020 propensity-matched study of 4,518 hospitalised patients given amiodarone and 4,518 controls states that amiodarone is associated with major bleeding during warfarin therapy. The size of the effect depended on kidney function: warfarin sensitivity rose by 36% in people with normal kidney function but by only 11.8% in people with severe kidney impairment, and the risk of an excessively high International Normalized Ratio (INR, the standard clotting-time test) rose in people with normal kidney function (hazard ratio 1.80) but was negligible with severe kidney impairment (hazard ratio 1.01).
- Timing. In a 2008 anticoagulation-clinic study of 70 patients, 102 of 2,434 International Normalized Ratio values (4%) were above 5. The relative risk of a value above 5 on combined warfarin and amiodarone versus warfarin alone was 1.366. Such values were most common during the first 12 weeks of combined therapy and required lower warfarin doses; no other notable changes occurred over the rest of the 80-week study.
The clotting test itself is described on the PT/INR page.
Digoxin. The 1984 pharmacokinetics review records reports of rising steady-state digoxin levels, together with signs of digitalis toxicity, when amiodarone was given to people on long-term digoxin. A 1987 study in healthy volunteers who took 200 mg of amiodarone daily for 2 weeks found that amiodarone increased the peak level and total exposure of oral digoxin; absolute bioavailability rose by 36% and 43% in the two subjects who received both oral and intravenous digoxin, and the authors concluded that increased absorption of oral digoxin is the most relevant change.
Statins. A 2010 Veterans Affairs report states that the US Food and Drug Administration revised the labels of amiodarone and simvastatin in 2002 to warn of an increased risk of rhabdomyolysis (severe muscle breakdown, the most severe form of myopathy) when the two are taken together with simvastatin doses above 20 mg per day. The agency reissued the warning in 2008 after receiving 52 reports of rhabdomyolysis following the 2002 label changes, and suggested an alternative statin for people on amiodarone who require more than 20 mg of simvastatin. At that Veterans Affairs centre, 92 patients were on amiodarone together with simvastatin 40 mg or 80 mg daily, and most of them had additional risk factors for myopathy. A 2020 clinical review lists simvastatin and atorvastatin, warfarin and many HIV antiretroviral medications among the drugs amiodarone interacts with.
Monitoring Described by Guidelines and Reviews
This section reports what guidelines and study authors describe; decisions about any individual's medicines belong with their clinicians.
- Liver and thyroid every 6 months. The 2017 Scottish study describes UK national guidelines recommending laboratory monitoring of liver and thyroid function every 6 months during long-term use. In practice, only 46%, 28% and 21% of patients had liver, thyroid and combined testing in line with the guidelines, and 13% and 17% had no ALT or TSH test at all; the authors call adherence suboptimal.
- Thyroid, lungs and liver. The 2020 clinical review states that routine monitoring is recommended for thyroid abnormalities, pulmonary fibrosis and raised liver enzymes (transaminitis). The 2024 review describes thyroid dysfunction, pulmonary fibrosis and hepatic injury as reasons for regular follow-up.
- Thyroid timing. The Icelandic authors call for frequent thyroid monitoring during the high-risk first and third years of treatment. The Korean authors write that regular thyroid function assessments are warranted when amiodarone is used, particularly in people at high risk of thyroid dysfunction.
- Eyes. The authors of the 2012 optic neuropathy review write that close eye surveillance during amiodarone therapy is warranted.
- Lung screening tests have limits. In the Japanese study, a fall of 15% or more in lung diffusing capacity identified pulmonary toxicity with a sensitivity of 68% and a specificity of 69%; a blood marker (KL-6 at or above 500 U/ml) had a sensitivity of 25% and a specificity of 91%.
What Remains Unknown
- The true rate of lung toxicity at today's doses. Published figures range from under 1% to 17%, and the large Israeli study of low-dose use did not find a statistically significant link, while the Japanese low-dose study found a 10.6% cumulative incidence at 5 years.
- Whether amiodarone causes optic neuropathy. The Taiwanese study found a doubled risk, but the 1999 review states no causal link had been proved, and the overlap with ischaemic optic neuropathy makes individual cases hard to attribute.
- How often thyroid disease really occurs. Reported rates differ several-fold between countries and study designs, and the 2025 Icelandic study found a 5-year rate higher than previously described.
- The best monitoring schedule for the liver. The 2008 liver review states that prospective studies have been sparse and that experts have not agreed on optimum monitoring.
- The full list of interactions. The 1989 interaction review states that prospective controlled studies are still needed on many likely drug combinations.
Key Research Papers
- Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018;7(2):55-66. PubMed PMID: 29594056
- Sohn SY, Kim YJ, Cho S, Cho SW. Incidence and Risk Factors for Amiodarone-Induced Thyroid Dysfunction: A Nationwide Retrospective Cohort Study. Am J Cardiovasc Drugs. 2025;25(3):419-425. PubMed PMID: 39798058
- Guðjónsson P, Jóhannesson AJ, Eyþórsson E, Andersen K. Amiodarone induced thyroid dysfunction: A high cumulative incidence in a nationwide cohort study in Iceland. J Intern Med. 2025;298(3):228-236. PubMed PMID: 40637127
- Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240-54. PubMed PMID: 11294826
- Ylli D, Wartofsky L, Burman KD. Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders. J Clin Endocrinol Metab. 2021;106(1):226-236. PubMed PMID: 33159436
- Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem. 1989;35(9):1882-7. PubMed PMID: 2673586
- Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991;31(11):1061-9. PubMed PMID: 1753010
- Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9(2):136-56. PubMed PMID: 6370540
- Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312-22. PubMed PMID: 17878423
- Hamilton D Sr, Nandkeolyar S, Lan H, Desai P, et al. Amiodarone: A Comprehensive Guide for Clinicians. Am J Cardiovasc Drugs. 2020;20(6):549-558. PubMed PMID: 32166725
- Șorodoc V, Indrei L, Dobroghii C, Asaftei A, et al. Amiodarone Therapy: Updated Practical Insights. J Clin Med. 2024;13(20):6094. PubMed PMID: 39458044
- Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791-8. PubMed PMID: 9283542
- Ruzieh M, Moroi MK, Aboujamous NM, Ghahramani M, et al. Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo. Am J Cardiol. 2019;124(12):1889-1893. PubMed PMID: 31653351
- Bongard V, Marc D, Philippe V, Jean-Louis M, et al. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther. 2006;13(4):315-9. PubMed PMID: 16858166
- Rankin S, Elder DH, Ogston S, George J, et al. Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovasc Ther. 2017;35(3). PubMed PMID: 28276175
- Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010;33(7):539-58. PubMed PMID: 20553056
- Yamada Y, Shiga T, Matsuda N, Hagiwara N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J. 2007;71(10):1610-6. PubMed PMID: 17895560
- Tsaban G, Ostrovsky D, Alnsasra H, Burrack N, et al. Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study. Eur Heart J. 2024;45(5):379-388. PubMed PMID: 37939798
- Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol. 1999;84(9A):37R-45R. PubMed PMID: 10568658
- Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6(3):228-36. PubMed PMID: 18673162
- Cheng HC, Yeh HJ, Huang N, Chou YJ, et al. Amiodarone-Associated Optic Neuropathy: A Nationwide Study. Ophthalmology. 2015;122(12):2553-9. PubMed PMID: 26391464
- Passman RS, Bennett CL, Purpura JM, Kapur R, et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med. 2012;125(5):447-53. PubMed PMID: 22385784
- Mitchell R, Chacko J. Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy. Biomolecules. 2022;12(9):1298. PubMed PMID: 36139137
- Lesko LJ. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet. 1989;17(2):130-40. PubMed PMID: 2673606
- Heimark LD, Wienkers L, Kunze K, Gibaldi M, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51(4):398-407. PubMed PMID: 1563209
- Miano TA, Yang W, Shashaty MGS, Zuppa A, et al. The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. Clin Pharmacol Ther. 2020;107(6):1446-1456. PubMed PMID: 32112562
- Lu Y, Won KA, Nelson BJ, Qi D, et al. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm. 2008;65(10):947-52. PubMed PMID: 18463344
- Santostasi G, Fantin M, Maragno I, Gaion RM, et al. Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects. J Cardiovasc Pharmacol. 1987;9(4):385-90. PubMed PMID: 2438499
- Karimi S, Hough A, Beckey C, Parra D. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm. 2010;16(7):472-81. PubMed PMID: 20726676
PubMed Topic Searches
Connections
- Drugs — every drug page on the site
- Iodine Excess: Thyroiditis — how a large iodine load inflames the thyroid
- Iodine Excess: Thyroid Dysfunction — iodine and thyroid hormone levels
- Atrial Fibrillation — the most common rhythm amiodarone is used for
- Ventricular Tachycardia — the rhythm its approval covers
- Hypothyroidism — the underactive thyroid
- Hyperthyroidism — the overactive thyroid
- PT/INR — the clotting test the warfarin interaction moves
- Thyroid Panel — the thyroid blood tests